عرض بسيط للتسجيلة

المؤلفChemaitelly, Hiam
المؤلفYassine, Hadi M.
المؤلفBenslimane, Fatiha M.
المؤلفAl Khatib, Hebah A.
المؤلفTang, Patrick
المؤلفHasan, Mohammad R.
المؤلفMalek, Joel A.
المؤلفCoyle, Peter
المؤلفAyoub, Houssein H.
المؤلفAl Kanaani, Zaina
المؤلفAl Kuwari, Einas
المؤلفJeremijenko, Andrew
المؤلفKaleeckal, Anvar Hassan
المؤلفLatif, Ali Nizar
المؤلفShaik, Riyazuddin Mohammad
المؤلفAbdul Rahim, Hanan F.
المؤلفNasrallah, Gheyath K.
المؤلفAl Kuwari, Mohamed Ghaith
المؤلفAl Romaihi, Hamad Eid
المؤلفAl-Thani, Mohamed H.
المؤلفAl Khal, Abdullatif
المؤلفButt, Adeel A.
المؤلفBertollini, Roberto
المؤلفAbu-Raddad, Laith J.
تاريخ الإتاحة2021-10-20T07:59:40Z
تاريخ النشر2021-09-01
اسم المنشورNature Medicine
المعرّفhttp://dx.doi.org/10.1038/s41591-021-01446-y
الاقتباسChemaitelly, H., Yassine, H.M., Benslimane, F.M. et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med 27, 1614–1621 (2021). https://doi.org/10.1038/s41591-021-01446-y
الرقم المعياري الدولي للكتاب10788956
معرّف المصادر الموحدhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85110038106&origin=inward
معرّف المصادر الموحدhttp://hdl.handle.net/10576/24582
الملخصThe SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a randomized clinical trial. Here, we assess the real-world effectiveness of this vaccine against SARS-CoV-2 variants of concern, specifically B.1.1.7 (Alpha) and B.1.351 (Beta), in Qatar, a population that comprises mainly working-age adults, using a matched test-negative, case-control study design. We show that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose. Effectiveness against B.1.1.7 infection was 88.1% (95% confidence interval (CI): 83.7–91.5%) ≥14 days after the first dose but before the second dose, and was 100% (95% CI: 91.8–100.0%) ≥14 days after the second dose. Analogous effectiveness against B.1.351 infection was 61.3% after the first dose (95% CI: 56.5–65.5%) and 96.4% after the second dose (95% CI: 91.9–98.7%). Effectiveness against any severe, critical or fatal COVID-19 disease due to any SARS-CoV-2 infection (predominantly B.1.1.7 and B.1.351) was 81.6% (95% CI: 71.0–88.8%) and 95.7% (95% CI: 73.4–99.9%) after the first and second dose, respectively. The mRNA-1273 vaccine is highly effective against B.1.1.7 and B.1.351 infections, whether symptomatic or asymptomatic, and against any COVID-19 hospitalization and death, even after a single dose.
اللغةen
الموضوعEpidemiology
RNA vaccines
Viral infection
العنوانmRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
النوعArticle
الصفحات1614-1621
رقم العدد9
رقم المجلد27
ESSN1546-170X
dc.accessType Abstract Only


الملفات في هذه التسجيلة

الملفاتالحجمالصيغةالعرض

لا توجد ملفات لها صلة بهذه التسجيلة.

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة